Table 1A |
|
Control |
Group A |
Sample ID |
MAST 1035 |
MAST 1261 |
MAST 1194 |
MAST 0931 |
MAST 0227 |
Date Collected |
01/04/11 |
05/20/11 |
04/05/11 |
10/27/10 |
06/10/09 |
Diagnosis Date |
12/28/10 |
4/28/11 |
3/18/11 |
8/15/07 |
5/29/09 |
Sarcoma pathological subtype |
Myxofibro-sarcoma |
Synovial Sarcoma |
Myxofibro-sarcoma |
PNST |
Leiomyo-sarcoma |
Primary Lesion Site |
L Forearm |
Thigh |
R Thigh |
Thigh |
L Calf |
Sample Lesion Site |
L Forearm |
L Thigh |
R Thigh |
Lung |
L Calf |
Disease Status (Local vs. Metastatic) |
Local |
Local |
Local |
Metastatic |
Local |
Prior Radiation (XRT) to Sample |
No |
No |
No |
Yes |
No |
% Necrosis of Sample |
0 |
0 |
0 |
0 |
0 |
PRE Collection Treatment |
None |
1. Excision |
None |
Excision & XRT to primary |
None |
Status Post Collect |
NED |
+ lung met 6/21/11 |
+ lung met 5/5/11 |
NED |
NED |
POST Collection Treatment |
2. XRT arm; 3. Obs |
3. Ifos/Adria |
2. XRT |
Obs |
2. Gem/Tax |
Ratio of MTDH/β-actin |
0 |
1.04 |
1.23 |
0.18 |
1.22 |
HotAir (RNA) |
1 |
846 |
10.5 |
112 |
77.2 |
Table 1B |
|
Control |
Group B |
Sample ID |
MAST 1035 |
MAST 0850 |
MAST 0703 |
MAST 1139 |
MAST 0796 |
Date Collected |
01/04/11 |
09/17/10 |
05/18/10 |
03/29/11 |
08/13/10 |
Diagnosis Date |
12/28/10 |
6/15/10 |
7/9/09 |
10/4/07 |
2/17/06 |
Sarcoma pathological subtype |
Myxofibro-sarcoma |
Leiomyo-sarcoma |
Leiomyo-sarcoma |
Leiomyo-sarcoma |
Leiomyo-sarcoma |
Primary Lesion Site |
L Forearm |
R Thigh |
Uterus |
Uterus |
L Groin |
Sample Lesion Site |
L Forearm |
R Thigh |
Colon |
Abdomen |
Adrenal gland |
Disease Status (Local vs. Metastatic) |
Local |
Local |
Metastatic |
Met, recurr |
Metastatic |
Prior Radiation (XRT) to Sample |
No |
Yes |
No |
No |
Yes |
% Necrosis of Sample |
0 |
70% |
100% |
85% |
5% |
PRE Collection Treatment |
None |
1. Cis/Adria/ Mito w/XRT |
1. Hysterect 2. Gem/Tax |
1. Hysterect 2. Gem/Tax |
1. Gem/ tax; 2.Clin Trial; 3.Doxuribicin; 4.Dacarbazine |
Status Post Collect |
NED |
PD |
Concurr Gem/Tax |
NED |
SD--slow growing |
POST Collection Treatment |
2. XRT arm; 3. Obs |
3.Ifos |
3. Gem/Tax; 4. Excision; 5. VPA |
4. None, PD |
Obs |
Ratio of MTDH/β-actin |
0 |
0.38 |
0.17 |
0 |
0 |
HotAir (RNA) |
1 |
149 |
-2.7 |
78 |
780 |
Table 1C |
|
Control |
Group C |
Sample ID |
MAST 1035 |
MAST 0006 |
MAST 0268 |
MAST 0510 |
Date Collected |
01/04/11 |
11/19/08 |
07/10/09 |
01/22/10 |
Diagnosis Date |
12/28/10 |
11/5/08 |
4/14/09 |
5/6/09 |
Sarcoma pathological subtype |
Myxofibro-sarcoma |
Lipo-sarcoma, Myxoid |
Malignant Fibrous Histiocytoma |
Leiomyo-sarcoma |
Primary Lesion Site |
L Forearm |
Buttock |
Thigh |
L Leg |
Sample Lesion Site |
L Forearm |
Buttock |
Lung |
Lung |
Disease Status (Local vs. Metastatic) |
Local |
Metastatic |
Metastatic |
Metastatic |
Prior Radiation (XRT) to Sample |
No |
No |
No |
No |
% Necrosis of Sample |
0 |
0 |
0 |
0 |
PRE Collection Treatment |
None |
None |
1. Above knee amp |
1. Amp; 2.Gem/ Tax; 3.Lung resection |
Status Post Collect |
NED |
+ other met sites |
+ lung met 8/25/09 |
+ lung met 4/30/11 |
POST Collection Treatment |
2. XRT arm; 3. Obs |
None, PD |
None, PD |
None, PD |
Ratio of MTDH/β-actin |
0 |
0 |
2.1 |
1.62 |
HotAir (RNA) |
1 |
36.4 |
0.8 |
0.7 |